大塚 直亮 (オオツカ ナオアキ)

Otsuka Naoaki

写真a

職名

助教

科研費研究者番号

31002678

生年

1993年

研究室住所

字喜友名1076番地

メールアドレス

メールアドレス

現在の所属組織 【 表示 / 非表示 】

  • 専任   琉球大学   医学研究科   助教  

研究キーワード 【 表示 / 非表示 】

  • 睡眠障害

  • 概日リズム睡眠・覚醒障害

  • 双極症

研究分野 【 表示 / 非表示 】

  • 精神神経科学

主たる研究テーマ 【 表示 / 非表示 】

  • 睡眠障害

  • 双極症

論文 【 表示 / 非表示 】

  • Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials

    Maruki, T; Takeshima, M; Yoshizawa, K; Maeda, Y; Otsuka, N; Aoki, Y; Utsumi, T; Matsui, K; Tajika, A; Takaesu, Y

    PSYCHIATRY AND CLINICAL NEUROSCIENCES ( Psychiatry and Clinical Neurosciences )  79 ( 6 ) 306 - 318   2025年06月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    Combination therapy with antidepressants and sleep medications is a promising candidate treatment for major depressive disorder (MDD) with insomnia. This systematic review and meta-analysis examined the efficacy and safety of combination therapy with antidepressants and sleep medication for treating MDD with insomnia compared to antidepressant monotherapy by sleep medication class (benzodiazepine, Z-drug, melatonin receptor agonist, and orexin receptor antagonist). This study was preregistered with PROSPERO (CRD42025636571). PubMed, CENTRAL, and Embase were searched for double-blind randomized controlled trials published until June 2024, resulting in eight eligible studies (1945 participants; eszopiclone = 4, zolpidem = 2, triazolam = 1, ramelteon = 1). Meta-analyses were performed based on six trials of Z-drugs. Compared with antidepressant monotherapy, combination therapy with antidepressants and Z-drugs resulted in higher remission rates from depressive symptoms (risk ratio: 1.25, 95% confidence interval [CI]: 1.08-1.45, P = 0.003), greater improvement in depressive symptoms (standardized mean difference [SMD]: 0.17, 95% CI: 0.01-0.33, P = 0.04) and insomnia symptoms (SMD: 0.43, 95% CI: 0.28-0.59, P < 0.001) in the short-term (within 12 weeks), with no difference in safety outcomes except for dizziness. Combination therapy with antidepressants and Z-drugs may be more useful for MDD with insomnia symptoms than antidepressant monotherapy in the short term. However, this study did not evaluate the benefits and harms of long-term adjunctive Z-drug therapy. Further long-term studies are needed to draw definitive conclusions regarding the efficacy and safety of combination therapy with antidepressants and Z-drugs. Moreover, further research is warranted to assess whether the findings of this study are applicable to other sleep medication classes.

  • Depressive mixed state and anxious distress as risk factors for suicidal behavior during major depressive episodes

    Ota, K; Shinzato, H; Otsuka, N; Zamami, Y; Kurihara, K; Futenma, K; Kondo, T; Takaesu, Y

    SCIENTIFIC REPORTS ( Scientific Reports )  15 ( 1 ) 11918 - 11918   2025年04月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    Accurately assessing and predicting suicidal behavior in patients with depression are challenging for researchers and clinicians. We examined various risk factors for suicidal behavior during major depressive episodes (MDE), especially focusing on depressive mixed state (DMX) and anxious distress (AD). We recruited 187 patients with MDE and divided them into two groups-with and without suicidal behavior-defined as the cut-off score of 1 or more on the suicidal behavior sub-item in the quick inventory of depressive symptomatology-self report. The presence of DMX was defined as a total score of 13 or more on the self-administered 8-item questionnaire for DMX. We used multivariate logistic regression analysis with the presence or absence of suicidal behavior as a dependent variable for investigating factors associated with suicidal behavior. The with suicidal behavior group was younger and indicated a greater proportion of past suicide attempts, AD, and DMX than the without suicidal behavior group. Logistic regression analysis revealed that AD (P = 0.020) and DMX (P = 0.018) were significantly associated with suicidal behavior. AD and DMX may promote suicidal behavior during MDE. These two psychopathological features should be carefully monitored and intensively treated for the prevention of suicide-related events.

  • Elevated Brain-Derived Neurotrophic Factor Levels During Depressive Mixed States

    Otsuka, N; Takaesu, Y; Zamami, Y; Ota, K; Kurihara, K; Shinzato, H; Kondo, T

    PSYCHIATRY INVESTIGATION ( Psychiatry Investigation )  20 ( 11 ) 1027 - +   2023年11月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    OBJECTIVE: Neurotrophin-like brain-derived neurotrophic factor (BDNF) and pro-inflammatory cytokines may modulate the pathophysiology of mood disorders. Although several studies show alterations in these biomarkers during the depressive, manic, and euthymic states of mood disorders, evidence is lacking for those in a mixed state. Therefore, this study aimed to investigate the relationship between the depressive mixed state (DMX) and peripheral neurobiological factors. METHODS: We enrolled 136 patients with major depressive episodes. Depressive symptoms were assessed using the Quick Inventory of Depressive Symptomatology Self-Report Japanese version (QIDS-SR-J). The severity of DMX was assessed using the self-administered 12-item questionnaire (DMX-12). Categorical screening as DMX-positive (n=54) was determined by a cutoff score of 13 or more in the specific eight symptoms from the DMX-12; the remaining were DMX-negative (n=82). Serum BDNF, tumor necrosis factor-α, highsensitivity C-reactive protein, and interleukin-6 levels were measured. RESULTS: When comparing biomarkers between the DMX-positive and DMX-negative groups, higher serum BDNF concentration in the DMX-positive group than in the DMX-negative group was the only significant finding (p=0.009). A positive correlation existed between the total score of the eight specific symptoms of DMX-12 and the BDNF concentration (r=0.190, p=0.027). After adjustment for confounders, logistic regression analysis revealed that BDNF (odds ratio [OR]=1.07, 95% confidence interval [CI]=1.00-1.14, p=0.045), bipolar diagnosis (OR=3.43, 95% CI=1.36-8.66, p=0.009), and total QIDS-SR-J score (OR=1.29, 95% CI=1.15-1.43, p<0.001) were significantly associated with DMX positivity. CONCLUSION: BDNF was positively associated with DMX severity, suggesting that higher BDNF concentrations may be involved in the pathophysiology of DMX.

MISC(その他業績・査読無し論文等) 【 表示 / 非表示 】

  • 概日リズム睡眠-覚醒障害—Circadian rhythm sleep-wake disorders—特集 睡眠障害の診療update ; 睡眠障害の診療

    大塚 直亮, 高江洲 義和

    日本臨床 = Japanese journal of clinical medicine ( 東京 : 日本臨床社 )  83 ( 7 ) 963 - 969   2025年07月

     

  • 「ねむい」を診わける:日中の眠気,起床困難 気分障害と睡眠・概日リズム障害

    大塚直亮, 高江洲義和

    臨床精神医学   53 ( 1 )   2024年

     

    J-GLOBAL

  • 不眠症状を伴う大うつ病性障害に対する抗うつ薬と睡眠薬の併用療法の有効性と安全性:系統的レビューとメタ解析

    竹島正浩, 丸木拓, 吉沢和久, 前田優那, 大塚直亮, 青木裕見, 内海智博, 松井健太郎, 松井健太郎, 田近亜蘭, 高江洲義和, 高江洲義和

    日本睡眠学会定期学術集会プログラム・抄録集   48th   2024年  [査読有り]

     

    J-GLOBAL

  • Aerococcus urinaeによる尿路感染症の一例:当院での同菌感染症の検討を含めて

    大塚直亮, 知花なおみ, 眞志取多美

    沖縄医学会雑誌   58 ( 2 )   2020年  [査読有り]

     

    J-GLOBAL

学術関係受賞 【 表示 / 非表示 】

  • 沖縄精神神経学会 学会賞

    2025年02月   沖縄精神神経学会  

    受賞者: ■■■

科研費獲得情報 【 表示 / 非表示 】

  • Ca2+シグナリング変動による概日リズム障害を伴う双極性障害の時計遺伝子解析

    若手研究

    課題番号: 25K19085

    研究期間: 2025年04月  -  2028年03月 

    代表者: 大塚 直亮 

    直接経費: 3,700,000(円)  間接経費: 4,810,000(円)  金額合計: 1,110,000(円)

  • Ca2+シグナリング変動による概日リズム障害を伴う双極性障害の時計遺伝子解析

    若手研究

    課題番号: 25K19085

    研究期間: 2025年04月  -  2028年03月 

    代表者: 大塚 直亮 

    直接経費: 3,700,000(円)  間接経費: 4,810,000(円)  金額合計: 1,110,000(円)

  • 人工多能性幹細胞由来神経細胞を用いた概日リズム障害併存双極性障害の病態解明

    研究活動スタート支援

    課題番号: 24K23441

    研究期間: 2024年07月  -  2026年03月 

    代表者: 大塚 直亮 

    直接経費: 2,200,000(円)  間接経費: 2,860,000(円)  金額合計: 660,000(円)

  • 人工多能性幹細胞由来神経細胞を用いた概日リズム障害併存双極性障害の病態解明

    研究活動スタート支援

    課題番号: 24K23441

    研究期間: 2024年07月  -  2026年03月 

    代表者: 大塚 直亮 

    直接経費: 2,200,000(円)  間接経費: 2,860,000(円)  金額合計: 660,000(円)